Skip to content

Health inequalities: disparities in SGLT-2 inhibitor prescribing

A research grant is available for application to identify potential emerging gaps in SGLT-2 prescription and to suggest possible interventions.

We are interested in prescriptions made for chronic kidney disease (CKD) patients across primary and secondary care, although we welcome specific ideas and methods in applicants’ research proposals.

 

Why do we need this research? 

  • Results from clinical trials have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors have potential to manage cardiorenal risk. In chronic kidney disease (CKD) SGLT-2 inhibitors have shown particular benefit in reducing CKD progression in patients with type 2 diabetes, as well as those with albuminuric CKD without diabetes. These findings are reflected in recent NICE guidelines 
  • Overall SGLT-2 inhibitor prescription for CKD is still relatively low in the UK, yet some disparities have already been identified.
  • As one of the key interventions identified in our Health Economics report, we want to investigate SGLT-2 inhibitor prescription according to NICE guidelines in order to identify emerging disparities, and therefore identify which groups are less prescribed.
  • Health inequalities are well documented in kidney disease, and we ask applicants to consider groups at risk (see pages 46-49 of the Health Economics report), as well as any other groups that may be of interest. 

Grant information

Research project grant  

To design and deliver this research through to publication, with interim plans of how to disseminate findings before final publication. Successful applicants will be selected from assessment undertaken by a review panel.  

  • Funding available: up to £40k

Expectations

In collaboration with Kidney Research UK, the successful applicant will be expected to: 

  • Design a research proposal to address these needs 
  • Deliver the research project, collect and analyse data appropriately 
  • Include plans of result dissemination pre-final publication, so that change can be implemented if required 
  • Prepare a final manuscript for publication 
  • Propose and commit to a pre-agreed timeline, no longer than six months duration.

Eligibility

In order to be considered for this award, applicants should have/provide: 

  • Previous experience in research using electronic health record platforms 
  • A detailed budget breakdown of relevant costs
  • Outline their capacity to undertake the required work
  • By fully aware and compliant with GDPR regulations and data security measures
  • Agree to adhere to timelines set by Kidney Research UK
  • Be employed by a UK university or recognised research establishment  

How to make a submission

We are pleased to invite submissions from suitably qualified researchers to design and conduct this project to identify where there are potential gaps in SGLT-2 inhibitor prescription in people with guideline recommended indications.  

If you are interested in this opportunity, please send a submission (no more than 2 A4 pages plus a detailed budget plan) to grants@kidneyresearchuk.org stating ‘Health inequalities: disparities in SGLT-2 inhibitor prescribing’ as the subject line. 

If you have a question or would like further information contact grants@kidneyresearchuk.org.

Closing date for submissions: Now closed

Get our Research Roundup email

Stay up to date with our kidney research news.

Scroll To Top